177 related articles for article (PubMed ID: 3161613)
1. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
[TBL] [Abstract][Full Text] [Related]
2. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
[TBL] [Abstract][Full Text] [Related]
3. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
4. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
5. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
Klaassen DJ; Rapp EF; Hirte WE
Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
[TBL] [Abstract][Full Text] [Related]
6. ACTH and cortisol plasma levels in cancer patients treated with medroxyprogesterone acetate at high dosages.
Papaleo C; Carella C; Zito GA; Figlia A; Capuano F; Amato G
Chemioterapia; 1984 Aug; 3(4):220-2. PubMed ID: 6099752
[TBL] [Abstract][Full Text] [Related]
7. Adrenal function under long-term raloxifene administration.
Genazzani AR; Lombardi I; Borgioli G; di Bono I; Casarosa E; Gambacciani M; Palumbo M; Genazzani AD; Luisi M
Gynecol Endocrinol; 2003 Apr; 17(2):159-68. PubMed ID: 12737677
[TBL] [Abstract][Full Text] [Related]
8. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients.
Rose DP; Davis TE
Cancer Res; 1980 Nov; 40(11):4043-7. PubMed ID: 6451282
[TBL] [Abstract][Full Text] [Related]
9. Adrenal steroids as parameters of the bioavailability of MA and MPA.
Willemse PH; Dikkeschei LD; Tjabbes T; van Veelen H; Sleijfer DT
Eur J Cancer; 1990 Mar; 26(3):359-62. PubMed ID: 2141494
[TBL] [Abstract][Full Text] [Related]
10. The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
Dowsett M; Lal A; Smith IE; Jeffcoate SL
Br J Cancer; 1987 Mar; 55(3):311-3. PubMed ID: 2952154
[TBL] [Abstract][Full Text] [Related]
11. Megestrol acetate therapy and secondary adrenal suppression.
Naing KK; Dewar JA; Leese GP
Cancer; 1999 Sep; 86(6):1044-9. PubMed ID: 10491532
[TBL] [Abstract][Full Text] [Related]
12. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
[TBL] [Abstract][Full Text] [Related]
13. Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study.
Straub RH; Härle P; Yamana S; Matsuda T; Takasugi K; Kishimoto T; Nishimoto N
Arthritis Rheum; 2006 Jun; 54(6):1778-85. PubMed ID: 16729287
[TBL] [Abstract][Full Text] [Related]
14. Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients.
Wilking N; Carlström K; Sköldefors H; Theve NO; Wallgren A
Acta Chir Scand; 1982; 148(4):345-9. PubMed ID: 6215811
[TBL] [Abstract][Full Text] [Related]
15. Oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with advanced breast cancer.
Beex L; Burghouts J; van Turnhout J; Breed W; Hillen H; Holdrinet A; Boetius G; Hoogendoorn G; Doesburg W; Verhulst M
Cancer Treat Rep; 1987 Dec; 71(12):1151-6. PubMed ID: 3690524
[TBL] [Abstract][Full Text] [Related]
16. [Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer].
Mitsuyama S; Kuroda Y; Ohsato K; Nakamura Y; Murakami F; Nishikata F; Ikeda S; Egami T; Mori A; Ohe H
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1153-60. PubMed ID: 8751803
[TBL] [Abstract][Full Text] [Related]
17. Adrenal function in early and metastatic breast cancer: dexamethasone suppression of plasma cortisol.
Drafta DS; Stroe E; Schindler EE; Teodosiu T; Gozariu L; Drafta D
Endocrinologie; 1981; 19(2):115-21. PubMed ID: 6789444
[TBL] [Abstract][Full Text] [Related]
18. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis.
Hellman L; Yoshida K; Zumoff B; Levin J; Kream J; Fukushima DK
J Clin Endocrinol Metab; 1976 May; 42(5):912-7. PubMed ID: 178684
[TBL] [Abstract][Full Text] [Related]
19. [Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced phases of breast and endometrial cancer].
Bernardo-Strada MR; Imparato E; Aspesi G; Pavesi L; Robustelli Della Cuna G
Minerva Med; 1980 Nov; 71(44):3241-6. PubMed ID: 7454090
[TBL] [Abstract][Full Text] [Related]
20. Adequacy of estrogen suppression with aminoglutethimide and hydrocortisone as treatment of human breast cancer: correlation of hormonal data with clinical responses.
Santen RJ; Worgul TJ; Samojlik E; Boucher AE; Lipton A; Harvey H
Cancer Res; 1982 Aug; 42(8 Suppl):3397s-3401s. PubMed ID: 7083205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]